. 2022 Mar; 22(1):e4.
doi: 10.4110/in.2022.22.e4.

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody

Dain Moon 1 Nara Tae 2 Yunji Park 3 Seung-Woo Lee 1 Dae Hee Kim 4 
  • PMID: 35291652
  •     117 References


In the era of immunotherapeutic control of cancers, many advances in biotechnology, especially in Ab engineering, have provided multiple new candidates as therapeutic immuno-oncology modalities. Bispecific Abs (BsAbs) that recognize 2 different antigens in one molecule are promising drug candidates and have inspired an upsurge in research in both academia and the pharmaceutical industry. Among several BsAbs, T cell engaging BsAb (TCEB), a new class of therapeutic agents designed to simultaneously bind to T cells and tumor cells via tumor cell specific antigens in immunotherapy, is the most promising BsAb. Herein, we are providing an overview of the current status of the development of TCEBs. The diverse formats and characteristics of TCEBs, in addition to the functional mechanisms of BsAbs are discussed. Several aspects of a new TCEB-Blinatumomab-are reviewed, including the current clinical data, challenges of patient treatment, drawbacks regarding toxicities, and resistance of TCEB therapy. Development of the next generation of TCEBs is also discussed in addition to the comparison of TCEB with current chimeric antigen receptor-T therapy.

Keywords: Adverse effects; Bispecific antibodies; Blinatumomab; Cancer immunotherapy; Chimeric antigen receptor T cell therapy; T cell engager.

Continuous cultures of fused cells secreting antibody of predefined specificity.
G Köhler, C Milstein.
Nature, 1975 Aug 07; 256(5517). PMID: 1172191
Highly Cited.
Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.
J U Schmohl, M K Gleason, +2 authors, D A Vallera.
Target Oncol, 2015 Nov 15; 11(3). PMID: 26566946    Free PMC article.
Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety-A Systematic Review with Meta-Analysis.
Wen-Liang Yu, Zi-Chun Hua.
Cancers (Basel), 2019 Jan 10; 11(1). PMID: 30621018    Free PMC article.
The cellular and molecular origin of tumor-associated macrophages.
Ruth A Franklin, Will Liao, +5 authors, Ming O Li.
Science, 2014 May 09; 344(6186). PMID: 24812208    Free PMC article.
Highly Cited.
Blinatumomab for MRD+ B-ALL: the evidence strengthens.
Patrick Brown.
Blood, 2018 Apr 07; 131(14). PMID: 29622532
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, +32 authors, Stephan A Grupp.
N Engl J Med, 2018 Feb 01; 378(5). PMID: 29385370    Free PMC article.
Highly Cited.
Development of bispecific antibodies in China: overview and prospects.
Jing Zhang, Jizu Yi, Pengfei Zhou.
Antib Ther, 2021 May 01; 3(2). PMID: 33928227    Free PMC article.
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL.
Virginie Nägele, Andrea Kratzer, +8 authors, Matthias Klinger.
Exp Hematol Oncol, 2017 May 24; 6. PMID: 28533941    Free PMC article.
Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII.
Alexander Sternjak, Fei Lee, +8 authors, Matthias Friedrich.
Mol Cancer Ther, 2021 Feb 27; 20(5). PMID: 33632870
Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
Jeong A Park, Brian H Santich, +2 authors, Nai-Kong V Cheung.
J Immunother Cancer, 2021 May 15; 9(5). PMID: 33986124    Free PMC article.
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Hagop Kantarjian, Anthony Stein, +23 authors, Max S Topp.
N Engl J Med, 2017 Mar 02; 376(9). PMID: 28249141    Free PMC article.
Highly Cited.
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
Nicola Gökbuget, Gerhard Zugmaier, +11 authors, Ralf Bargou.
Haematologica, 2017 Jan 14; 102(4). PMID: 28082340    Free PMC article.
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells.
Simon J Dovedi, Matthew J Elder, +32 authors, Yariv Mazor.
Cancer Discov, 2021 Jan 10; 11(5). PMID: 33419761
Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
G J Weiner, J R Hillstrom.
J Immunol, 1991 Dec 01; 147(11). PMID: 1834746
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors.
N Haense, A Atmaca, +8 authors, S-E Al-Batran.
BMC Cancer, 2016 Jul 09; 16. PMID: 27387446    Free PMC article.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, +19 authors, Tanya Siddiqi.
Lancet, 2020 Sep 06; 396(10254). PMID: 32888407
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, +9 authors, George Coukos.
N Engl J Med, 2003 Jan 17; 348(3). PMID: 12529460
Highly Cited.
Function-specific variations in the immunological synapses formed by cytotoxic T cells.
Darrell J Irvine.
Proc Natl Acad Sci U S A, 2003 Nov 19; 100(24). PMID: 14623966    Free PMC article.
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
Jérôme Galon, Anne Costes, +13 authors, Franck Pagès.
Science, 2006 Sep 30; 313(5795). PMID: 17008531
Highly Cited.
Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
B Cochlovius, S M Kipriyanov, +4 authors, M Little.
Cancer Res, 2000 Sep 02; 60(16). PMID: 10969772
Recombination of a mixture of univalent antibody fragments of different specificity.
Arch Biochem Biophys, 1961 May 01; 93. PMID: 13729244
Highly Cited.
γδ T cell activation by bispecific antibodies.
Hans-Heinrich Oberg, Christian Kellner, +5 authors, Daniela Wesch.
Cell Immunol, 2015 May 17; 296(1). PMID: 25979810
Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
M Mack, R Gruber, +2 authors, P Kufer.
J Immunol, 1997 Apr 15; 158(8). PMID: 9103467
Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells.
Archana Thakur, John Scholler, +4 authors, Lawrence G Lum.
Front Immunol, 2021 Jul 23; 12. PMID: 34290709    Free PMC article.
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Daniel W Lee, James N Kochenderfer, +16 authors, Crystal L Mackall.
Lancet, 2014 Oct 17; 385(9967). PMID: 25319501    Free PMC article.
Highly Cited.
A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Zachery Halford, Carli Coalter, Vanessa Gresham, Tabitha Brown.
Ann Pharmacother, 2021 Jan 14; 55(10). PMID: 33435716
Systematic Review.
Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation.
O Manzke, H Tesch, +5 authors, H Bohlen.
Int J Cancer, 2001 Mar 17; 91(4). PMID: 11251974
Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.
D Lu, H Kotanides, +5 authors, Z Zhu.
J Immunol Methods, 1999 Dec 14; 230(1-2). PMID: 10594363
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
Seongju Jeong, Eunyoung Park, +19 authors, Jaeho Jung.
J Immunother Cancer, 2021 Jul 08; 9(7). PMID: 34230109    Free PMC article.
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
A Löffler, P Kufer, +6 authors, R C Bargou.
Blood, 2000 Mar 09; 95(6). PMID: 10706880
Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation.
C Demanet, J Brissinck, J De Jonge, K Thielemans.
Blood, 1996 May 15; 87(10). PMID: 8639800
Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
Sara Raponi, Maria Stefania De Propris, +7 authors, Anna Guarini.
Leuk Lymphoma, 2011 Feb 26; 52(6). PMID: 21348573
Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.
Belén Blanco, Carmen Domínguez-Alonso, Luis Alvarez-Vallina.
Clin Cancer Res, 2021 Jun 11; 27(20). PMID: 34108185
Subsets of myeloid-derived suppressor cells in tumor-bearing mice.
Je-In Youn, Srinivas Nagaraj, Michelle Collazo, Dmitry I Gabrilovich.
J Immunol, 2008 Oct 04; 181(8). PMID: 18832739    Free PMC article.
Highly Cited.
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.
M Mack, G Riethmüller, P Kufer.
Proc Natl Acad Sci U S A, 1995 Jul 18; 92(15). PMID: 7624362    Free PMC article.
A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer.
Daniel A Vallera, Felix Oh, +4 authors, Martin Felices.
Cancers (Basel), 2021 Aug 28; 13(16). PMID: 34439149    Free PMC article.
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Max S Topp, Nicola Gökbuget, +17 authors, Ralf C Bargou.
J Clin Oncol, 2014 Nov 12; 32(36). PMID: 25385737
Highly Cited.
CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.
Björn Engelbrekt Wahlin, Birgitta Sander, Birger Christensson, Eva Kimby.
Clin Cancer Res, 2007 Jan 27; 13(2 Pt 1). PMID: 17255259
Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party.
Sung-Hoon Jung, Se-Ryeon Lee, +16 authors, Ho-Jin Shin.
Ann Hematol, 2018 Sep 28; 98(1). PMID: 30259121
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
Jörg U Schmohl, Martin Felices, +5 authors, Daniel A Vallera.
Cancer Res Treat, 2017 Feb 24; 49(4). PMID: 28231426    Free PMC article.
Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice.
J A Titus, M A Garrido, +3 authors, D M Segal.
J Immunol, 1987 Jun 01; 138(11). PMID: 3108382
Hybrid hybridomas and their use in immunohistochemistry.
C Milstein, A C Cuello.
Nature, 1983 Oct 06; 305(5934). PMID: 6137772
Highly Cited.
Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
Rajkumar Ganesan, Vijaykumar Chennupati, +3 authors, Iqbal S Grewal.
Leukemia, 2021 Feb 03; 35(8). PMID: 33526858    Free PMC article.
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Keunchil Park, Eric B Haura, +31 authors, Byoung Chul Cho.
J Clin Oncol, 2021 Aug 03; 39(30). PMID: 34339292    Free PMC article.
Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.
Jan P Bogen, Stefania C Carrara, +3 authors, Harald Kolmar.
Front Immunol, 2021 May 28; 12. PMID: 34040611    Free PMC article.
The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
Hermann Einsele, Hossein Borghaei, +6 authors, Hagop M Kantarjian.
Cancer, 2020 May 14; 126(14). PMID: 32401342
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Nathan D Trinklein, Duy Pham, +16 authors, Shelley Force Aldred.
MAbs, 2019 Jan 31; 11(4). PMID: 30698484    Free PMC article.
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.
Maxim Kebenko, Marie-Elisabeth Goebeler, +14 authors, Walter Fiedler.
Oncoimmunology, 2018 Sep 18; 7(8). PMID: 30221040    Free PMC article.
Tumor immunosurveillance in human cancers.
Bernhard Mlecnik, Gabriela Bindea, Franck Pagès, Jérôme Galon.
Cancer Metastasis Rev, 2011 Jan 21; 30(1). PMID: 21249426    Free PMC article.
Cytokine release syndrome after radiation therapy: case report and review of the literature.
Christopher A Barker, Samuel K Kim, +3 authors, Sandra P D'Angelo.
J Immunother Cancer, 2018 Jan 05; 6(1). PMID: 29298730    Free PMC article.
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Christina L Zuch de Zafra, Flordeliza Fajardo, +13 authors, Olivier Nolan-Stevaux.
Clin Cancer Res, 2019 Mar 29; 25(13). PMID: 30918018
Highly Cited.
Preliminary trial of specific targeting therapy against malignant glioma.
T Nitta, K Sato, +2 authors, S Ishii.
Lancet, 1990 Feb 17; 335(8686). PMID: 1968115
Catumaxomab: clinical development and future directions.
Rolf Linke, Anke Klein, Diane Seimetz.
MAbs, 2010 Mar 02; 2(2). PMID: 20190561    Free PMC article.
A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity.
Wenlong Tan, Yanchun Meng, +7 authors, Yajun Guo.
MAbs, 2014 Feb 05; 5(6). PMID: 24492346    Free PMC article.
Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors.
Jürgen Borlak, Florian Länger, +2 authors, Christian Dittrich.
Oncotarget, 2016 Apr 09; 7(19). PMID: 27058902    Free PMC article.
Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
P Kufer, M Mack, +3 authors, G Riethmüller.
Cancer Immunol Immunother, 1998 Jan 22; 45(3-4). PMID: 9435872
Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
Ying Cheng, Xiaodong Zheng, +5 authors, Haoyu Sun.
Cancer Biol Med, 2020 Dec 11; 17(4). PMID: 33299651    Free PMC article.
Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.
J S Huston, D Levinson, +7 authors, R Crea.
Proc Natl Acad Sci U S A, 1988 Aug 01; 85(16). PMID: 3045807    Free PMC article.
Highly Cited.
High level secretion of a humanized bispecific diabody from Escherichia coli.
Z Zhu, G Zapata, +3 authors, P Carter.
Biotechnology (N Y), 1996 Feb 01; 14(2). PMID: 9636323
Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions.
Diana Romero.
Nat Rev Clin Oncol, 2021 Aug 13; 18(10). PMID: 34381206
T cell-engaging therapies - BiTEs and beyond.
Maria-Elisabeth Goebeler, Ralf C Bargou.
Nat Rev Clin Oncol, 2020 Apr 04; 17(7). PMID: 32242094
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.
Donald A Berry, Shouhao Zhou, +7 authors, Jerald P Radich.
JAMA Oncol, 2017 May 12; 3(7). PMID: 28494052    Free PMC article.
Highly Cited.
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Andreas Viardot, Marie-Elisabeth Goebeler, +10 authors, Ralf C Bargou.
Blood, 2016 Jan 13; 127(11). PMID: 26755709    Free PMC article.
Highly Cited.
Origins of tumor-associated macrophages and neutrophils.
Virna Cortez-Retamozo, Martin Etzrodt, +17 authors, Mikael J Pittet.
Proc Natl Acad Sci U S A, 2012 Feb 07; 109(7). PMID: 22308361    Free PMC article.
Highly Cited.
Tumor hypoxia represses γδ T cell-mediated antitumor immunity against brain tumors.
Jang Hyun Park, Hyun-Jin Kim, +10 authors, Heung Kyu Lee.
Nat Immunol, 2021 Feb 13; 22(3). PMID: 33574616
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.
Vincenzo Bronte, Paolo Serafini, +9 authors, Paola Zanovello.
J Immunol, 2002 Dec 24; 170(1). PMID: 12496409
Highly Cited.
Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA).
B Robert, M Dorvillius, +5 authors, A Pèlegrin.
Int J Cancer, 1999 Apr 03; 81(2). PMID: 10188732
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
David T Teachey, Susan R Rheingold, +11 authors, Stephan A Grupp.
Blood, 2013 May 17; 121(26). PMID: 23678006    Free PMC article.
Highly Cited.
Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia.
Craig A Portell, Candice M Wenzell, Anjali S Advani.
Clin Pharmacol, 2013 May 15; 5(Suppl 1). PMID: 23671399    Free PMC article.
Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
Nicola Bortoletto, Emmanuel Scotet, +2 authors, Antonio Lanzavecchia.
Eur J Immunol, 2002 Oct 18; 32(11). PMID: 12385030
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Sarah B Reusing, Dan A Vallera, +6 authors, Florian Babor.
Cancer Immunol Immunother, 2021 Aug 17; 70(12). PMID: 34398302    Free PMC article.
Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.
Ibrahim Aldoss, Samer K Khaled, Elizabeth Budde, Anthony S Stein.
Curr Oncol Rep, 2019 Jan 23; 21(1). PMID: 30666425
Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling.
Srinivas Nagaraj, Allison Nelson, +3 authors, Dmitry I Gabrilovich.
Cancer Res, 2012 Jan 13; 72(4). PMID: 22237629    Free PMC article.
CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity.
Ji Li, Robert Piskol, +9 authors, Teemu T Junttila.
Sci Transl Med, 2019 Sep 06; 11(508). PMID: 31484792
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
Arend von Stackelberg, Franco Locatelli, +20 authors, Lia Gore.
J Clin Oncol, 2016 Dec 22; 34(36). PMID: 27998223
Highly Cited.
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.
Patrick Hoffmann, Robert Hofmeister, +6 authors, Patrick A Baeuerle.
Int J Cancer, 2005 Feb 03; 115(1). PMID: 15688411
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, +22 authors, JULIET Investigators.
N Engl J Med, 2018 Dec 07; 380(1). PMID: 30501490
Highly Cited.
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
Giovanni Martinelli, Nicolas Boissel, +10 authors, Anthony Stein.
J Clin Oncol, 2017 Mar 30; 35(16). PMID: 28355115
Highly Cited.
Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells.
S M Kipriyanov, G Moldenhauer, G Strauss, M Little.
Int J Cancer, 1998 Aug 04; 77(5). PMID: 9688311
Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
C Renner, W Jung, +7 authors, M Pfreundschuh.
Science, 1994 May 06; 264(5160). PMID: 8171337
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Max S Topp, Nicola Gökbuget, +22 authors, Hagop M Kantarjian.
Lancet Oncol, 2014 Dec 20; 16(1). PMID: 25524800
Highly Cited.
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.
Johannes Duell, Dragana S Lukic, +9 authors, Max S Topp.
J Immunother, 2019 May 16; 42(5). PMID: 31090657
Affinity enhancement of bispecific antibody against two different epitopes in the same antigen.
H S Cheong, J S Chang, J M Park, S M Byun.
Biochem Biophys Res Commun, 1990 Dec 31; 173(3). PMID: 1702631
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning.
Lauric Haber, Kara Olson, +41 authors, Eric Smith.
Sci Rep, 2021 Jul 15; 11(1). PMID: 34257348    Free PMC article.
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
Martin Sebastian, Bernward Passlick, +7 authors, Alexander Schmittel.
Cancer Immunol Immunother, 2007 Apr 06; 56(10). PMID: 17410361
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.
Hongyan Liu, Abhishek Saxena, Sachdev S Sidhu, Donghui Wu.
Front Immunol, 2017 Feb 12; 8. PMID: 28184223    Free PMC article.
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life.
Kevin O Saunders.
Front Immunol, 2019 Jun 25; 10. PMID: 31231397    Free PMC article.
Highly Cited. Review.
Dual targeting strategies with bispecific antibodies.
Roland E Kontermann.
MAbs, 2012 Mar 29; 4(2). PMID: 22453100    Free PMC article.
Highly Cited. Review.
Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays.
M R Suresh, A C Cuello, C Milstein.
Proc Natl Acad Sci U S A, 1986 Oct 01; 83(20). PMID: 2429324    Free PMC article.
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
Ana C Anderson, Nicole Joller, Vijay K Kuchroo.
Immunity, 2016 May 19; 44(5). PMID: 27192565    Free PMC article.
Highly Cited. Review.
'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization.
J B Ridgway, L G Presta, P Carter.
Protein Eng, 1996 Jul 01; 9(7). PMID: 8844834
Highly Cited.
Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells.
Felicita Baratelli, Ying Lin, +7 authors, Steven M Dubinett.
J Immunol, 2005 Jul 22; 175(3). PMID: 16034085
Highly Cited.
Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments.
M Brennan, P F Davison, H Paulus.
Science, 1985 Jul 05; 229(4708). PMID: 3925553
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
S Canevari, G Stoter, +7 authors, C H Lamers.
J Natl Cancer Inst, 1995 Oct 04; 87(19). PMID: 7674333
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Max S Topp, Peter Kufer, +26 authors, Ralf C Bargou.
J Clin Oncol, 2011 May 18; 29(18). PMID: 21576633
Highly Cited.
Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components.
D Mezzanzanica, S Canevari, +4 authors, M I Colnaghi.
Int J Cancer, 1988 Apr 15; 41(4). PMID: 3258590
Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.
Hervé Dombret, Max S Topp, +6 authors, Hagop Kantarjian.
Leuk Lymphoma, 2019 Apr 06; 60(9). PMID: 30947585
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Markus M Heiss, Pawel Murawa, +17 authors, Simon L Parsons.
Int J Cancer, 2010 May 18; 127(9). PMID: 20473913    Free PMC article.
Highly Cited.
CAR-NK cells: A promising cellular immunotherapy for cancer.
Guozhu Xie, Han Dong, +3 authors, Jianzhu Chen.
EBioMedicine, 2020 Aug 28; 59. PMID: 32853984    Free PMC article.
Human NK cells, their receptors and function.
Linda Quatrini, Mariella Della Chiesa, +3 authors, Lorenzo Moretta.
Eur J Immunol, 2021 Apr 27; 51(7). PMID: 33899224
CAR-T cells and BiTEs in solid tumors: challenges and perspectives.
Julien Edeline, Roch Houot, Aurélien Marabelle, Marion Alcantara.
J Hematol Oncol, 2021 Apr 21; 14(1). PMID: 33874996    Free PMC article.
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Maria-Elisabeth Goebeler, Stefan Knop, +21 authors, Ralf C Bargou.
J Clin Oncol, 2016 Feb 18; 34(10). PMID: 26884582
Highly Cited.
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
Joost Neijssen, Rosa M F Cardoso, +8 authors, Mark L Chiu.
J Biol Chem, 2021 Apr 12; 296. PMID: 33839159    Free PMC article.
CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Miguel Gaspar, John Pravin, +6 authors, Neil Brewis.
Cancer Immunol Res, 2020 Apr 11; 8(6). PMID: 32273279
B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes.
Gihoon You, Yangsoon Lee, +18 authors, Seung-Woo Lee.
Sci Adv, 2021 Feb 02; 7(3). PMID: 33523913    Free PMC article.
The inhibitory cytokine IL-35 contributes to regulatory T-cell function.
Lauren W Collison, Creg J Workman, +7 authors, Dario A A Vignali.
Nature, 2007 Nov 23; 450(7169). PMID: 18033300
Highly Cited.
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, +37 authors, William Y Go.
N Engl J Med, 2017 Dec 12; 377(26). PMID: 29226797    Free PMC article.
Highly Cited.
Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies.
H Lindhofer, R Mocikat, B Steipe, S Thierfelder.
J Immunol, 1995 Jul 01; 155(1). PMID: 7602098
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Anne Månsson Kvarnhammar, Niina Veitonmäki, +16 authors, Peter Ellmark.
J Immunother Cancer, 2019 Apr 13; 7(1). PMID: 30975201    Free PMC article.
An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation.
C Asseman, S Mauze, +2 authors, F Powrie.
J Exp Med, 1999 Oct 06; 190(7). PMID: 10510089    Free PMC article.
Highly Cited.
Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas.
J S Lewis, R J Landers, +2 authors, C E Lewis.
J Pathol, 2000 Sep 27; 192(2). PMID: 11004690
J Exp Med, 1964 Jan 01; 119. PMID: 14113110    Free PMC article.
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.
Noelle V Frey, David L Porter.
Hematology Am Soc Hematol Educ Program, 2016 Dec 04; 2016(1). PMID: 27913530    Free PMC article.
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies.
Gihoon You, Jonghwa Won, +4 authors, Seung-Woo Lee.
Vaccines (Basel), 2021 Aug 07; 9(7). PMID: 34358141    Free PMC article.
Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.
M Asokan, R S Rudicell, +21 authors, J R Mascola.
J Virol, 2015 Oct 09; 89(24). PMID: 26446600    Free PMC article.
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.
Dirk Nagorsen, Ralf Bargou, +3 authors, Gerhard Zugmaier.
Leuk Lymphoma, 2009 May 21; 50(6). PMID: 19455460
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Nicola Gökbuget, Hervé Dombret, +15 authors, Ralf C Bargou.
Blood, 2018 Jan 24; 131(14). PMID: 29358182    Free PMC article.
Highly Cited.